Apellis Pharmaceuticals Stock News

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares, rose in value on Friday, 11/26/21, with the stock price down by -3.27% to the previous days close as strong demand from buyers drove the stock to $43.54. Actively observing the price movement in the last trading, the stock closed the session at $45.01, falling within a range of $42.84 Is Now A Good Time To Invest In Apellis Pharmaceuticals Inc. (NASDAQ: APLS)? Read More »

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been assigned a consensus recommendation of Buy from the fourteen brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average []

The trading price of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) closed lower on Monday, November 22, closing at $43.13, -1.82% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) major shareholder Morningside Venture Investment bought 250,000 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, November 18th. The stock was acquired at an average cost of $40.00 per share, with a total value of $10,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which []

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previ

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Apellis to 10,062,500 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by Apellis, to $402.5 million.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price closed higher on Tuesday, November 16, jumping 11.95% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

In the latest trading session, 1.94 million Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares changed hands as the companys beta touched 1.62. With the companys most recent per share price at $45.55 changing hands around $3.47 or 8.25% at last look, the market valuation stands at $3.29B. APLSs current price is a discount, trading about -60.26% off Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Is Rated A Buy By Analysts. Read More »

Ipswich Investment Management Co. Inc. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 14.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,265 shares of the companys stock after acquiring an additional 2,815 shares during the quarter. Ipswich Investment Management Co. Inc.s []

Related Stocks: ELEV , APLS ,

Related Stocks: APLS , CLDX , BBIO , RCUS , IPSC , CTKB , OMGA , TENX , ZLAB , XLRN , TSHA , KYMR , MRUS , RVMD ,

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis Treatment Candidate Keza

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,312,500 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on November 18, 2021, subject to customary closing conditions.